Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Xianbao Zhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3718-466X; OpenAlex author ID A5100749666. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 trial · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Biomimetic MXene nanoplatform for tumor-specific synergistic phototherapy and immune reprogramming in pancreatic cancer. Last author DOI 10.1039/d6bm00210b↗
  2. KAT8 catalyzes the acetylation of SEPP1 at lysine 247/249 and modulates the activity of CD8+ T cells via LRP8 to promote anti-tumor immunity in pancreatic canc… Co-author DOI 10.1186/s13578-025-01356-3↗
  3. Autologous ex vivo expanded NK cells combined with PD-1 inhibitor improved ascitic fluid immune microenvironment of peritoneal metastatic pancreatic cancer: a … Last author PMID 36777837↗
  4. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  5. Application of natural killer cells in pancreatic cancer. Last author DOI 10.3892/ol.2021.12908↗
  6. LKB1 obliterates Snail stability and inhibits pancreatic cancer metastasis in response to metformin treatment. Co-author DOI 10.1111/cas.13591↗
  7. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. Co-author DOI 10.1038/ajg.2011.281↗
  8. Incidence of pancreatic cancer in chinese patients with chronic pancreatitis. Co-author DOI 10.1159/000322982↗

Trials 1

  1. Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma Principal investigator NCT03159819↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaobo Peng · 4 shared papers, 2018–2025 · strength 0.75
  2. Ling Chen · 2 shared papers, 2021–2023 · strength 0.34
  3. Dan Ding · 1 shared paper, 2025 · strength 0.33
  4. Zhongfei Zhu · 1 shared paper, 2025 · strength 0.33
  5. Gang Nie · 1 shared paper, 2025 · strength 0.33
  6. Wei Li · 1 shared paper, 2026 · strength 0.26
  7. Tong Yin · 1 shared paper, 2026 · strength 0.26
  8. Yanfang Liu · 1 shared paper, 2023 · strength 0.18
  9. Meng Guo · 1 shared paper, 2023 · strength 0.18
  10. Jie Chen · 2 shared papers, 2011–2022 · strength 0.12
  11. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  12. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  13. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  14. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  15. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  16. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  17. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  18. Gang Ren · 1 shared paper, 2022 · strength 0.09
  19. Dan Cao · 1 shared paper, 2022 · strength 0.09
  20. Jian Wang · 1 shared paper, 2022 · strength 0.09
  21. Yongrui Bai · 1 shared paper, 2022 · strength 0.09
  22. Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
  23. Yongwei Sun · 1 shared paper, 2022 · strength 0.09
  24. Ji Li · 1 shared paper, 2022 · strength 0.09
  25. Jianping Xiong · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.